Contineum Therapeutics (CTNM) Retained Earnings (2023 - 2026)

Contineum Therapeutics' Retained Earnings history runs 4 years deep, the most recent figure standing at -$253000.0 for Q1 2026.

• In Q1 2026, Retained Earnings fell 248.82% year-over-year to -$253000.0; the TTM figure through Mar 2026 stood at -$253000.0 (down 248.82% YoY), while the FY2025 annual figure was -$177.4 million, down 51.09% from the prior year.
• Retained Earnings was -$253000.0 for Q1 2026 at Contineum Therapeutics, up from -$177.4 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $170000.0 in Q1 2025 to a low of -$177.4 million in Q4 2025.
• Historically, Retained Earnings has averaged -$96.1 million across 4 years, with a median of -$97.7 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Retained Earnings jumped 100.2% in 2025, then slumped 248.82% in 2026.
• A 4-year view of Retained Earnings shows it stood at -$75.1 million in 2023, then plunged by 56.24% to -$117.4 million in 2024, then tumbled by 51.09% to -$177.4 million in 2025, then jumped by 99.86% to -$253000.0 in 2026.
• The last three Retained Earnings figures came in at -$253000.0 (Q1 2026), -$177.4 million (Q4 2025), and -$162.2 million (Q3 2025), per Business Quant data.